Hydroxychloroquine and Azithromycin as Prophylaxis for Healthcare Workers Dealing With COVID19 Patients

Inclusion Criteria: * Medical doctors, Nurses and Respiratory therapists caring for COVID-19 patients in ER and ICU and dedicated COVID19 units. * Age between 18 and 70 years old. * Male or non-pregnant, non- lactating female. * Availability for follow up by phone. * Willing to participate and provide signed informed consent. Exclusion Criteria: * Subjects with a history of retinopathy, sickle cell disease or trait, psoriasis, or porphyria. * Subjects who take certain prescribed or over the counter (OTC) concomitant medication including ampicillin, cimetidine, digoxin, statins, cyclosporine, warfarin, fluconazole, within 2 weeks of dosing start, and during the duration of the study. * Current Symptoms of Fever, Cough, or Shortness of Breath. * PCR confirmed positive test of COVID-19. * Weight \< 40 kg. * Pregnant (positive β-human chorionic gonadotropin test, β-HCG) or lactating female at the screening. * Allergy to any of the study medications. * History of splenectomy. * Infection with hepatitis B or C viruses. * Chronic or active neurologic disease including seizure disorder and chronic migraine headaches. * Any abnormal baseline laboratory screening tests listed below * Aspartate aminotransferase (AST) or alanine aminotransferase (ALT)above twice the upper limit of normal for the reference lab. * Creatinine above the normal range. * Hemoglobin for males \<12.5 g/dl and females \<10.5 g/dl. * Platelet count of \<150 X 103/L. * Total white blood cell (WBC) count out of normal range Note: If screening lab values are out of the normal range but are expected to be temporary (e.g. due to dehydration), they may be re-assessed one more time at the discretion of the investigator. * An abnormal baseline screening ECG suggestive of cardiac disease as determined by a clinical investigator. QTcF of \>450 msec for males and \>470 msec for females. * Any other significant finding that based on the judgment of the PI would increase the risk of having an adverse outcome from participating in this study * Subjects known to have a mental illness * Subjects who have Skin disorders (including rash, dermatitis, and psoriasis) * Hematological disease. * Cardiovascular disease. * G6PD deficiency. * Lactose intolerance.